Biomarkers in pharmacology and drug discovery

Biochemical Pharmacology

Volumn 87, Issue 1, 2014, Pages 172-188

  Anderson, D C ^a   Kodukula, Krishna ^a,b  

^a SRI INTERNATIONAL   (United States)

^b JAMES MADISON UNIVERSITY   (United States)

Author keywords

Biomarkers; Disease diagnosis biomarker discovery; Polypharmacy; Protein biomarkers

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BCR ABL PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CETUXIMAB; CRIZOTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; NILOTINIB; OLAPARIB; PANITUMUMAB; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; TAMOXIFEN; TRASTUZUMAB; VELIPARIB; VEMURAFENIB;

BIOINFORMATICS; CLINICAL PATHWAY; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; DATA ANALYSIS; DRUG DEVELOPMENT; DRUG TARGETING; GENETIC ASSOCIATION; HUMAN; INFORMATION PROCESSING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; POLYPHARMACY; PRIORITY JOURNAL; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; REVIEW; STATISTICAL ANALYSIS; STUDY DESIGN; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

BIOMARKERS; DISEASE DIAGNOSIS BIOMARKER DISCOVERY; POLYPHARMACY; PROTEIN BIOMARKERS;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; DRUG DISCOVERY; HUMANS; NEOPLASMS; PHARMACOLOGY;

EID: 84892374338     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.08.026     Document Type: Review

References (295)

1. G. Poste Bring on the biomarkers Nature 469 2011 156 157
2. N. Rifai, M. Gillette, and S.A. Carr Protein biomarker discovery and validation: the long and uncertain path to clinical utility Nat Biotech 24 2005 971 983 (Pubitemid 44215392)
3. J. Cummings, F. Raynaud, L. Jones, R. Sugar, C. Dive On behalf of the Bioanalysis and Quality Assurance (BAQA) Group of the ECMC Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs Br J Cancer 103 2010 1313 1317
4. V. Puntmann How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease Postgrad Med J 85 2009 538 545
5. G. Szekely-Klepser, and S. Fountain Validation of biochemical biomarker assays used in drug discovery and development: a review of challenges and solutions J. Williams, J.A. Lalonde, R. Koup, J.R.D.D. Christ, Predictive Approaches in Drug Discovery and Development: Biomarkers and in Drug Discovery and Development 2012 Wiley Hoboken 23 48
6. D. Flood, G. Marek, and M. Williams Developing predictive CSF biomarkers - a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine Biochem Pharmacol 81 2011 1422 1434
7. C.P. Paweletz, J.N. Andersen, R. Pollock, K. Nagashima, and M.L. Hayashi et al. Identification of direct target engagement biomarkers for kinase-targeted therapeutics PLoS ONE 6 2011 e26459
8. A. Atkinson, W. Colburn, V. DeGruttola, D. DeMets, G. Downing, and D. Hoth et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95 (Pubitemid 32225406)
9. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 2003 566 580 (Pubitemid 37361748)
10. J.E. Dancey, K.K. Dobbin, S. Groshen, J.M. Jessup, A.H. Hruszkewycz, and M. Koehler et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents Clin Cancer Res 16 2010 1745 1755
11. C. Oldenhuis, S. Oosting, J. Gietema, and E. de Vries Prognostic versus predictive value of biomarkers in oncology Eur J Cancer 44 2008 946 953
12. L. Rausch, C. Green, K. Steinmetz, S. LeValley, P. Catz, and N. Zaveri et al. Preclinical pharmacokinetic toxicological and biomarker evaluation of SR 16157, a novel dual-acting steroid sulfatase inhibitor and selective estrogen receptor modulator Cancer Chemother Pharmacol 67 2011 1341 1352
13. J.A. Canick, E.M. Kloza, G.M. Lambert-Messerlian, J.E. Haddow, M. Ehrich, and D. van den Boom et al. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations Prenat Diagn 32 2012 730 734
14. R. Xi, T.-M. Kim, and P. Park Detecting structural variations in the human genome using next generation sequencing Briefings Funct Genomics 9 2011 405 415
15. I. Riedmaier, and M. Pfaffl Transcriptional biomarkers - High throughput screening, quantitative verification, and bioinformatical validation methods Methods 59 2013 3 9
16. D.A. Ahlquist, H. Zou, M. Domanico, D.W. Mahoney, T.C. Yab, and W.R. Taylor et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas Gastroenterology 142 2012 248 256
17. J.B. Nikas, and W.C. Low Linear discriminant functions in connection with the micro-RNA diagnosis of colon cancer Cancer Inf 11 2012 1 14
18. L.J. Thal, K. Kantarci, E.M. Reiman, W.E. Klunk, M.W. Weiner, and H. Zetterberg et al. The role of biomarkers in clinical trials for Alzheimer disease Alzheimer Dis Assoc Disord 20 2006 6 15 (Pubitemid 44356888)
19. B.T. Klassen, J.G. Hentz, H.A. Shill, E. Driver-Dunckley, V.G. Evidente, and M.N. Sabbagh et al. Quantitative EEG as a predictive biomarker for Parkinson disease dementia Neurology 77 2011 118 124
20. P. Yu, R.A. Dean, S.D. Hall, Y. Qi, G. Sethuraman, and B.A. Willis et al. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia J Alzheimers Dis 32 2012 373 385
21. G. Bain, and R. Petty Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers The Oncologist 15 2010 270 284
22. N.S. Schoonenboom, W.M. van der Flier, M.A. Blankenstein, F.H. Bouwman, and G.J. Van Kamp et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease Neurobiol Aging 29 2008 669 675 (Pubitemid 351400823)
23. D. Zhang, Y. Wang, L. Zhou, H. Yuan, D. Shen the Alzheimer's Disease Neuroimaging Initiative 1 Multimodal classification of Alzheimer's disease and mild cognitive impairment NeuroImage 55 2011 856 867
24. A. Shtilbans, and C. Henchcliffe Biomarkers in Parkinson's disease: an update Curr Opin Neurol 25 2012 460 465
25. E. Lonn The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases Pharmacoepidemiol Drug Saf 10 2001 497 508 (Pubitemid 34100777)
26. T.M. Heinonen, M. Aamer, C. Marshall, D.M. Black, and J.C. Tardif Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges Expert Rev Cardiovasc Ther 10 2012 989 994
27. D.M. Nathan, B. Balkau, E. Bonora, K. Borch-Johnsen, J.B. Buse, and S. Colagiuri et al. International expert committee report on the role of the A1C assay in the diagnosis of diabetes Diab Care 32 2009 1327 1334
28. M. Buyse, D.J. Sargent, A. Grothey, A. Matheson, and A. de Gramont Biomarkers and surrogate end points- the challenge of statistical validation Nat Rev Clin Oncol 7 2009 309 317
29. E. Rosenberg, J. Baniel, Y. Spector, A. Faerman, E. Meiri, and R. Aharonov et al. Predicting progression of bladder urothelial carcinoma using microRNA expression BJU Int Feb 6 2013 epub
30. R. Goncalves, and R. Bose Using multigene tests to select treatment for early-stage breast cancer J Natl Compr Canc Netw 11 2013 174 182
31. C. Markopoulos Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer Expert Rev Anticancer Ther 13 2013 179 194
32. D. Jelovac, and A.C. Wolff The adjuvant treatment of HER2-positive breast cancer Curr Treat Options Oncol 13 2012 230 239
33. Y.J. Bang Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer J Clin Gastroenterol 46 2012 637 648
34. J.N. McAlpine, K.C. Wiegand, R. Vang, B.M. Ronnett, A. Adamiak, and M. Köbel et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy BMC Cancer 9 2009 433
35. R.L. Schilsky Personalized medicine in oncology: the future is now Nat Rev Drug Discov 9 363 2010 366
36. K. Beelen, W. Zwart, and S.C. Linn Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol 9 2012 529 541
37. S. Ali, and R.C. Coombes Estrogen receptor alpha in human breast cancer: occurrence and significance J Mammary Gland Biol Neoplasia 5 2000 271 281 (Pubitemid 32156528)
38. J.S. Ross, W.F. Symmans, L. Pusztai, and G. Hortobagyi Standardizing slide-based assays in breast cancer: Hormone receptors, HER2, and sentinel lymph nodes Clin Cancer Res 13 2007 2831 2835 (Pubitemid 46849556)
39. A. Lopez-Chavez, and G. Giaccone Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer Nat Rev Clin Oncol 7 2010 360 362
40. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
41. D.M. Jackman, V.A. Miller, L.A. Cioffredi, B.Y. Yeap, P.A. Janne, and G.J. Riely et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials Clin Cancer Res 15 2009 5267 5273
42. F. Lopez-Rios, B. Angulo, B. Gomez, D. Mair, R. Martinez, and E. Conde et al. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer J Clin Pathol 66 2013 381 385
43. H. Linardou, I.J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, and P. Kosmidis et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972
44. L. Hutchinson Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations Nat Rev Clin Oncol 7 2010 549
45. C.B. Begg, R.W. Haile, A. Borg, K.E. Malone, P. Concannon, and D.C. Thomas et al. Variation of breast cancer risk among BRCA1/2 carriers JAMA 299 2008 194 201
46. M. Deininger, and B. Druker Specific targeted therapy of chronic myelogenous leukemia with imatinib Pharmacol Rev 55 2003 401 423 (Pubitemid 37013211)
47. T. Terasawa, I. Dahabreh, and T. Trikalinos BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia PLoS Curr 2 2010 RRN1204
48. D. Diverio, R. Riccioni, F. Mandelli, and F. Lo Coco The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia Haematologica 80 1995 155 160
49. Z.Y. Wang, and Z. Chen Acute promyelocytic leukemia: from highly fatal to highly curable Blood 111 2008 2505 2515
50. A. Reiter, E. Lengfelder, and D. Grimwade Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia Acta Haematol 112 2004 55 67 (Pubitemid 38716250)
51. D. Gajria, and S. Chandarlapaty HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies Expert Rev Anticancer Ther 11 2011 263 275
52. M. Cuadros, and M. Villegas Systematic review of HER2 breast cancer testing Appl Immunohistochem Mol Morphol 17 2009 107
53. K.S. Smalley, and V.K. Sondak Melanoma - an unlikely poster child for personalized cancer therapy N Engl J Med 363 2010 876 878
54. F. Ong, K. Das, J. Wang, H. Vakil, J. Kuo, and B. Wendell-Lamar et al. Personalized medicine and pharmacogenetic biomarkers Expert Rev Molec Diag 12 2012 593 602
55. M.P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro, and D. Conte et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues Am J Pathol 174 2009 661 670
56. A.T. Shaw, B. Solomon, and M.M. Kenudson Crizotinib and testing for ALK J Natl Compr Canc Netw 9 2011 1335 1341
57. N. La Thangue, and D. Kerr Predictive biomarkers: a paradigm shift towards personalized cancer medicine Nat Rev Clin Oncol 8 2011 587 596
58. U. Rix, and G. Superti-Furga Target profiling of small molecules by chemical proteomics Nat Chem Biol 5 2009 616 624
59. U. Rix, O. Hantschel, G. Dürnberger, L.L. Remsing Rix, M. Planyavsky, and N.V. Fernbach et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 110 2007 4055 4063 (Pubitemid 350248462)
60. M. Talpaz, N.P. Shah, and H. Kantarjian et al. Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias N Engl J Med 354 2006 2531 2541 (Pubitemid 43882349)
61. D. Brehmer, Z. Greff, K. Godl, S. Blencke, and A. Kurtenbach et al. Cellular targets of gefitinib Cancer Res 65 2005 379 382
62. L. Zhang, O. Gjoerup, and T.M. Roberts The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling Proc Natl Acad Sci USA 101 2004 10296 10301 (Pubitemid 38924919)
63. J.R. Prensner, A. Chinnaiyan, and S. Srivastava Systematic, evidence-based discovery of biomarkers at the NCI Clin Exp Metastasis 29 2012 645 652
64. T. Voskoglou-Nomikos, J.L. Pater, and L. Seymour Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models Clin Cancer Res 9 2003 4227 4239 (Pubitemid 37204044)
65. P. McGonigle, and B.A. Ruggeri Animal Models of Human Disease: challenges in enabling translation Biochem Pharmacol 87 2014 162 171
66. M. Day, F. Balci, H.I. Wan, G.B. Fox, and J.L. Rutkowski Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic Curr Opin Investig Drugs 9 2008 696 706 (Pubitemid 351950866)
67. E.J. Nestler, and S.E. Hyman Animal models of neuropsychiatric disorders Nat Neurosci 13 2010 1161 1169
68. P. McGonigle Animal Models of CNS disorders Biochem Pharmacol 87 2014 140 149
69. E. Diamandis Cancer biomarkers: Can we turn recent failures into success? J Natl Cancer Inst 102 2010 1462 1467
70. G. Pendyala, S.A. Trauger, E. Kalisiak, R.J. Ellis, G. Siuzdak, and H.S. Fox Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys J Proteome Res 8 2009 2253 2260
71. C.R. Liang, S. Tan, H.T. Tan, Q. Lin, T.K. Lim, and Y. Liu et al. Proteomic analysis of human gastric juice: a shotgun approach Proteomics 10 2010 3928 3931
72. D. Elashoff, H. Zhou, J. Reiss, J. Wang, H. Xiao, and B. Henson et al. Prevalidation of salivary biomarkers for oral cancer detection Cancer Epidemiol Biomarkers Prev 21 2012 664 672
73. P. Fehlbaum-Beurdeley, A.C. Jarrige-Le Prado, D. Pallares, J. Carrière, C. Guihal, and C. Soucaille et al. Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression Alzheimers Dement 6 2010 25 38
74. M.K. Tuck, D.W. Chan, D. Chia, A.K. Godwin, W.E. Grizzle, and K.E. Krueger et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group J Proteome Res 8 2009 113 117
75. T. Addona, X. Shi, H. Keshishian, D. Mani, M. Burgess, and M. Gillette et al. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease Nat Biotechnol 29 2011 635 653
76. G. Wallstrom, K.S. Anderson, and J. Labaer Biomarker discovery for heterogeneous diseases Cancer Epidemiol Biomarkers Prev 22 2013 747 755
77. S.A. Villeda, J. Luo, K.I. Mosher, B. Zou, M. Britschgi, and G. Bieri et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function Nature 477 2011 90 94
78. X. Yang, and I.M. Lazar MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides BMC Cancer 9 2009 96
79. B.C. Liu, D.A. Dijohnson, and D.J. O'Rourke Antibody profiling with protein antigen microarrays in early stage cancer Expert Opin Med Diagn 6 2012 187 196
80. S. Oka, H. Furukawa, K. Shimada, H. Hayakawa, N. Fukui, and N. Tsuchiya et al. Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease BMC Immunol 14 2013 9
81. D.A. Wolters, M.P. Washburn, and J.R. Yates 3rd. An automated multidimensional protein identification technology for shotgun proteomics Anal Chem 73 2001 5683 5690 (Pubitemid 33126725)
82. D.F. Hunt, J.R. Yates, 3rd, J. Shabanowitz, S. Winston, and C.R. Hauer Protein sequencing by tandem mass spectrometry Proc Natl Acad Sci USA 83 1986 6233 6237 (Pubitemid 17174712)
83. L. Dayon, C. Pasquarello, C. Hoogland, J.C. Sanchez, and A. Scherl Combining low- and high-energy tandem mass spectra for optimized peptide quantification with isobaric tags J Proteomics 73 2010 769 777
84. S.E. Ong, B. Blagoev, I. Kratchmarova, D.B. Kristensen, H. Steen, and A. Pandey et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics Mol Cell Proteomics 1 2002 376 386
85. F. Gonzalez-Galarza, C. Lawless, S. Hubbard, J. Fan, C. Bessant, and H. Hermjakob et al. A critical appraisal of techniques, software packages, and standards for quantitative proteomic analysis J Integrative Biol 16 2012 431 442
86. Y. Ishihama, Y. Oda, T. Tabata, T. Sato, T. Nagasu, and J. Rappsilber et al. Exponentially modified Protein Abundance Index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein Mol Cell Proteomics 4 2005 1265 1272 (Pubitemid 41448714)
87. D.H. Lundgren, S.I. Hwang, L. Wu, and D.K. Han Role of spectral counting in quantitative proteomics Exp Rev Proteomics 7 2010 39 53
88. A. Michalski, E. Damoc, J.P. Hauschild, O. Lange, A. Wieghaus, and A. Makarov et al. Mass spectrometry- based proteomics using Q exactive, a high-performance benchtop quadrupole orbitrap mass spectrometer Mol Cell Proteomics 10 M111 2011 011015
89. T. Geiger, S. Madden, W. Gallagher, J. Cox, and M. Mann Proteomic portrait of human breast cancer progression identifies novel prognostic markers Cancer Res 72 2012 2428 2439
90. T. Geiger, A. Wehner, C. Schaab, J. Cox, and M. Mann Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins Mol Cell Proteomics 11 M111 2012 014050
91. T.W. Hutchins, and T.T. Yip New desorption strategies for the mass spectrometric analysis of macromolecules Rapid Commun Mass Spectrom 7 1993 576
92. J. Albrethsen The first decade of MALDI protein profiling: a lesson in translational biomarker research J Proteomics 74 2011 765 773
93. E.P. Diamandis Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations Mol Cell Proteomics 3 2004 367 378 (Pubitemid 38702090)
94. M.A. Karpova, S.A. Moshkovskii, I.Y. Toropygin, and A.I. Archakov Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives J Proteomics 73 2010 537 551
95. E. Krause, H. Wenschuh, and P.R. Jungblut The dominance of arginine-containing peptides in MALDI- derived tryptic mass fingerprints of proteins Anal Chem 71 1999 4160 4165 (Pubitemid 29466391)
96. G. Schlosser, G. Pocsfalvi, E. Huszár, A. Malorni, and F. Hudecz MALDI-TOF mass spectrometry of a combinatorial peptide library: effect of matrix composition on signal suppression J Mass Spectrom 40 2005 1590 1594 (Pubitemid 43048629)
97. L. Ekblad, B. Baldetorp, M. Ferno, H. Olsson, and C. Bratt In-source decay causes artifacts in SELDI-TOF MS spectra J Proteome Res 6 2007 1609 1614 (Pubitemid 46724058)
98. K.A. Baggerly, J.S. Morris, S.R. Edmonson, and K.R. Coombes Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer J Natl Cancer Inst 97 2005 307 309 (Pubitemid 40310279)
99. R. Xu, A. Gamst, and Re: Lessons from controversy: Ovarian cancer screening and serum proteomics J Natl Cancer Inst 97 2005 1227 1226; author reply
100. D.F. Ransohoff Lessons from controversy: ovarian cancer screening and serum proteomics J Natl Cancer Inst 97 2005 315 319 (Pubitemid 40310281)
101. J. Albrethsen Reproducibility in protein profiling by MALDI-TOF mass spectrometry Clin Chem 53 2007 852 858 (Pubitemid 46744240)
102. J. Albrethsen, R. Bøgebo, J. Olsen, H. Raskov, and S. Gammeltoft Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum Clin Chem Lab Med 44 2006 1243 1252 (Pubitemid 44580807)
103. J. Zou, G. Hong, X. Guo, L. Zhang, C. Yao, and J. Wang et al. Reproducible cancer biomarker discovery in SELDI-TOF MS using different pre-processing algorithms PLoS One 6 2011 e26294
104. E. Szájli, T. Fehér, and K.F. Medzihradszky Investigating the quantitative nature of MALDI-TOF MS Mol Cell Proteomics 7 2008 2410 2418
105. E.F. Petricoin, A.M. Ardekani, B.A. Hitt, P.J. Levine, V.A. Fusaro, and S.M. Steinberg et al. Use of proteomic patterns in serum to identify ovarian cancer Lancet 359 2002 572 577 (Pubitemid 34178440)
106. D. McLerran, W.E. Grizzle, Z. Feng, W.L. Bigbee, L.L. Banez, and L.H. Cazares et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias Clin Chem 54 2008 44 52 (Pubitemid 351182595)
107. D. McLerran, W.E. Grizzle, Z. Feng, I.M. Thompson, W.L. Bigbee, and L.H. Cazares et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer Clin Chem 54 2008 53 60 (Pubitemid 351182596)
108. S. Putri, S. Yamamoto, H. Tsugawa, and E. Fukusaki Current metabolomics: technological advances J Biosci Bioeng 116 2013 9 16
109. R. Ramautar, G.W. Somsen, and G.J. de Jong CE-MS for metabolomics: developments and applications in the period 2010-2012 Electrophoresis 34 2013 86 98
110. R. Mandal, A.C. Guo, K.K. Chaudhary, P. Liu, F.S. Yallou, and E. Dong et al. Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update Genome Med 4 2012 38
111. A.W. Boots, J.J. van Berkel, J.W. Dallinga, A. Smolinska, E.F. Wouters, and F.J. van Schooten The versatile use of exhaled volatile organic compounds in human health and disease J Breath Res 6 2012 027108
112. A. Smolinska, L. Blanchet, L.M. Buydens, and S.S. Wijmenga NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review Anal Chim Acta 750 2012 82 97
113. G. Theodoridis, H. Gika, E. Want, and I. Wilson Liquid chromatography-mass spectrometry based global metabolite profiling: a review Anal Chim Acta 711 2012 7 16
114. Y. Park, K. Lee, Q. Soltow, F. Strobel, K. Brigham, and R. Parker et al. High-performance metabolic profiling of plasma from seven mammalian species for simultaneous environmental chemical surveillance and bioeffect monitoring Toxicology 295 2012 47 55
115. E. Werner, K. Heilier, C. Ducruix, E. Ezan, J. Junot, and J. Tabet Mass spectrometry for the identification of the discriminating signals from metabolomics: current status and future trends Chromatogr B 871 2008 143 163
116. D.P. Jones, Y. Park, and T.R. Ziegler Nutritional metabolomics: progress in addressing complexity in diet and health Ann Rev Nutr 32 1-18 2012 18 20
117. K. Uppal, Q. Soltow, F. Strobel, W. Pittard, K. Gernert, and T. Yu et al. xMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data BMC Bioinformatics 14 2013 15 27
118. Y. Sato, I. Suzuki, T. Nakamura, F. Bernier, K. Aoshima, and Y. Oda Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology J Lipid Res 53 2012 567 576
119. R. Mishur, and S. Rea Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases Mass Spectrom Rev 31 2011 70 905
120. D. Vuckovic Current trends and challenges in sample preparation for global metabolomics using liquid chromatography-mass spectrometry Anal Bioanal Chem 403 2012 1523 1548
121. Z. León, J.C. García-Cañaveras, M.T. Donato, and A. Lahoz Mammalian cell metabolomics: experimental design and sample preparation Electrophoresis February 22 2013
122. A. Korman, A. Oh, A. Raskind, and D. Banks Statistical methods in metabolomics M. Anisimova, Evolutionary genomics: statistical and computational methods, vol. 2 2012 Springer 381 413
123. G.E. Alexander, K. Chen, P. Pietrini, S.I. Rapoport, E.M. Reiman, and P.E.T. Longitudinal evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies Am J Psychiatry 159 2002 738 745 (Pubitemid 34465046)
124. D. Silverman, G. Small, C. Chang, C. Lu, M. Kung De Aburto, and W. Chen et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome J Am Med Assoc 286 2001 2120 2127 (Pubitemid 34041597)
125. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Ann Neurol 55 2004 306 319 (Pubitemid 38269583)
126. S. Swaminathan, L. Shen, S.L. Risacher, K.K. Yoder, J.D. West, and S. Kim et al. Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort Brain Imaging Behav 6 2012 1 15
127. I. Greeve, I. Hermans-Borgmeyer, C. Brellinger, D. Kasper, T. Gomez-Isla, and C. Behl et al. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress J Neurosci 20 2000 7345 7352
128. R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, A. Goate, and N.C. Fox et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 367 2012 795 804
129. K. Schwamborn, and R.M. Caprioli MALDI imaging mass spectrometry - painting molecular pictures Mol Oncol 4 2010 529 538
130. T.M. Morgan, E.H. Seeley, O. Fadare, R.M. Caprioli, and P.E. Clark Imaging the clear cell renal cell carcinoma proteome J Urol 189 2013 1097 1103
131. Y. Schober, S. Guenther, B. Spengler, and A. Römpp Single cell matrix-assisted laser desorption/ionization mass spectrometry imaging Anal Chem 84 2012 6293 6297
132. M. Stoeckli, D. Staab, M. Staufenbiel, K.H. Wiederhold, and L. Signor Molecular imaging of amyloid beta peptides in mouse brain sections using mass spectrometry Anal Biochem 311 2002 33 39 (Pubitemid 35463486)
133. M. Stoeckli, P. Chaurand, D. Hallahan, and R. Caprioli Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues Nat Med 7 2001 493
134. M.L. Reyzer, and R.M. Caprioli MALDI-MS-based imaging of small molecules and proteins in tissues Curr Opin Chem Biol 11 2007 29 35 (Pubitemid 46217921)
135. M.L. Reyzer, Y. Hsieh, K. Ng, W.A. Korfmacher, and R.M. Caprioli Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry J Mass Spectrom 38 2003 1081 1092 (Pubitemid 37407703)
136. S. Khatib-Shahidi, M. Andersson, J.L. Herman, T.A. Gillespie, and R.M. Caprioli Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry Anal Chem 78 2006 6448 6456 (Pubitemid 44418954)
137. T. Valdes-Gonzalez, N. Goto-Inoue, W. Hirano, H. Ishiyama, T. Hayasaka, and M. Setou et al. New approach for glyco- and lipidomics - molecular scanning of human brain gangliosides by TLC-Blot and MALDI-QIT-TOF MS J Neurochem 116 2011 678 683
138. Y. Schober, T. Schramm, B. Spengler, and A. Römpp Protein identification by accurate mass matrix-assisted laser desorption/ionization imaging of tryptic peptides Rapid Commun Mass Spectrom 25 2011 2475 2483
139. L. McDonnell, R. Heeren, P. Andren, M. Stoeckli, and G. Corthals Going forward: Increasing the accessibility of imaging mass spectrometry J Proteomics 7S 2012 S113 S125
140. E. Acquadro, C. Cabella, S. Ghiani, L. Miragoli, E.M. Bucci, and D. Corpillo Matrix-assisted laser desorption ionization imaging mass spectrometry detection of a magnetic resonance imaging contrast agent in mouse liver Anal Chem 81 2009 2779 2784
141. P.J. Trim, C.M. Henson, J.L. Avery, A. McEwen, M.F. Snel, and E. Claude et al. Matrix-assisted laser desorption/ionization-ion mobility separation-mass spectrometry imaging of vinblastine in whole body tissue sections Anal Chem 80 2008 8628 8634
142. A.F. Altelaar, I. Klinkert, K. Jalink, R.P. de Lange, R.A. Adan, and R.M. Heeren et al. Gold-enhanced biomolecular surface imaging of cells and tissue by SIMS and MALDI mass spectrometry Anal Chem 78 2006 734 742 (Pubitemid 43228580)
143. P. Nemes, and A. Vertes Laser ablation electrospray ionization for atmospheric pressure, in vivo, and imaging mass spectrometry Anal Chem 79 2007 8098 8106 (Pubitemid 350060006)
144. B. Spengler, and M. Hubert Scanning microprobe matrix-assisted laser desorption ionization (SMALDI) mass spectrometry: instrumentation for sub-micrometer resolved LDI and MALDI surface analysis J Am Soc Mass Spectrom 13 2002 735 748 (Pubitemid 36876027)
145. M. Koestler, D. Kirsch, A. Hester, A. Leisner, S. Guenther, and B. Spengler A high-resolution scanning microprobe matrix-assisted laser desorption/ionization ion source for imaging analysis on an ion trap/Fourier transform ion cyclotron resonance mass spectrometer Rapid Commun Mass Spectrom 22 2008 3275 3285
146. P.H. Pevsner, J. Melamed, T. Remsen, A. Kogos, F. Francois, and P. Kessler et al. Mass spectrometry MALDI imaging of colon cancer biomarkers: a new diagnostic paradigm Biomarkers Med 3 2009 55 69
147. D. Trede, S. Schiffler, M. Becker, S. Wirtz, K. Steinhorst, and J. Strehlow et al. Exploring three-dimensional matrix-assisted laser desorption/ionization imaging mass spectrometry data: three-dimensional spatial segmentation of mouse kidney Anal Chem 84 2012 6079 6087
148. H. Thiele, S. Heldmann, D. Trede, J. Strehlow, S. Wirtz, and W. Dreher et al., 2D and 3D MALDI-imaging: Conceptual strategies for visualization and data mining Biochim Biophys Acta March 4 2013 epub
149. E. Seeley, and R. Caprioli MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives Trends Biotechnol 29 2011 136 143
150. T.K. Sinha, S. Khatib-Shahidi, T.E. Yankeelov, K. Mapara, M. Ehtesham, and D.S. Cornett et al. Integrating spatially resolved three-dimensional MALDI. I.M.S. with in vivo magnetic resonance imaging Nat Methods 5 2008 57 59
151. R. Edmondson, and D. Russell Evaluation of matrix-assisted laser desorption ionization-time-of- flight mass measurement accuracy by using delayed extraction J Am Soc Mass Spectrom 7 1996 995 1001 (Pubitemid 26336902)
152. S.O. Deininger, M.P. Ebert, A. Fütterer, M. Gerhard, and C. Röcken MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers J Proteome Res 7 2008 5230 5236
153. L.A. McDonnell, G.L. Corthals, S.M. Willems, A. van Remoortere, R.J. van Zeijl, and A.M. Deelder Peptide and protein imaging mass spectrometry in cancer research J Proteomics 73 2010 1921 1944
154. P. Chaurand, M.E. Sanders, R.A. Jensen, and R.M. Caprioli Proteomics in diagnostic pathology - profiling and imaging proteins directly in tissue sections Am J Pathol 165 2004 1057 1068 (Pubitemid 39297713)
155. L.H. Cazares, D. Troyer, S. Mendrinos, R.A. Lance, J.O. Nyalwidhe, and H.A. Beydoun et al. Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal- regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue Clin Cancer Res 15 2009 5541 5551
156. S. Meding, U. Nitsche, B. Balluff, M. Elsner, S. Rauser, and C. Schone et al. Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging J Proteome Res 11 2012 1996 2003
157. S.O. Deininger, M. Becker, and D. Suckau Tutorial: Multivariate statistical treatment of imaging data for clinical biomarker discovery S. Rubakhin, J. Sweedler, Mass Spectrometry Imaging: Principles and Protocols, Methods in Molecular Biology 656 2010 385 404
158. D. Miura, Y. Fujimura, and H. Wariishi In situ metabolomic mass spectrometry imaging: Recent advances and difficulties J Proteomics 75 2012 5052 5060
159. H. Kilpinen, and J.C. Barrett How next-generation sequencing is transforming complex disease genetics Trends Genet 29 2013 23 30
160. J.B. Dubé, and R.A. Hegele Genetics 100 for cardiologists: basics of genome-wide association studies Can J Cardiol 29 2013 10 17
161. L. Bertram, C.M. Lill, and R.E. Tanzi The genetics of Alzheimer's disease: back to the future Neuron 68 2010 270 281
162. R. Xi, T.-M. Kim, and P. Park Detecting structural variations in the
163. M.J. Hangauer, I.W. Vaughn, and M.T. McManus Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs PLoS Genet 9 2013 e1003569
164. E. Fratkin, S. Bercovici, and D.A. Stephan The implications of ENCODE for diagnostics Nat Biotechnol 30 2012 1064 1065
165. R. Tanzi The genetics of Alzheimer disease Cold Spring Harb Perspect Med 2 2012 6296 6306
166. R.W. Mahley, and Y. Huang Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches Ann Neurol 65 2009 623 625
167. K. Morgan Three new pathways leading to Alzheimer's disease Neuropath Appl Neurobiol 37 2011 353 357
168. S. Ikegawa A short history of the genome-wide association study: where we were and where we are going Genomics Inform 10 2012 220 225
169. D. Shyr, and Q. Liu Next generation sequencing in cancer research and clinical application Biol Proc Online 15 2013 4 15
170. C.E. Krebs, and C. Paisán-Ruiz The use of next-generation sequencing in movement disorders Front Genet 3 2012 75
171. T. Gasser, J. Hardy, and Y. Mizuno Milestones in PD genetics Mov Disord 26 2011 1042 1048
172. A. Tsuji Genetics of neurodegenerative diseases: insights from high-throughput resequencing Human Molec Genetics 19 2010 R65 R70
173. A. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 2009 2055 2066
174. J. Hardy, P. Lewis, T. Revesz, A. Lees, and C. Paisan-Ruiz The genetics of Parkinson's syndromes: a critical review Curr Opin Genet Dev 19 2009 254 265
175. C. Vilariño-Güell, C. Wider, O.A. Ross, J.C. Dachsel, J.M. Kachergus, and S.J. Lincoln et al. VPS35 mutations in Parkinson disease Am J Hum Genet 289 2011 162 167
176. C. Paisan-Ruiz, O. Dogu, A. Yilmaz, H. Houlden, and A. Singleton SPG11 mutations are common in familial cases of complicated hereditary spastic paraplegia Neurology 70 2008 1384 1389 (Pubitemid 351521929)
177. M. Anheim, C. Lagier-Tourenne, G. Stevanin, M. Fleury, A. Durr, and I. Namer et al. SPG11 spastic paraplegia. A new cause of juvenile parkinsonism J Neurol 256 2009 104 108
178. S.B. Baylin DNA methylation and gene silencing in cancer Nat Clin Pract Oncol 2Suppl. 1 2005 S4 S11
179. S. Fukushige, and A. Horii DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers Tohoku J Exp Med 229 2013 173 185
180. L. de Boni, S. Tierling, S. Roeber, J. Walter, A. Giese, and H. Kretzschmar Next-generation sequencing reveals regional differences of the a-synuclein methylation state independent of Lewy body disease Neuromol Med 13 2011 310 320
181. A. Jowaed, I. Schmitt, O. Kaut, and U. Wüllner Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains J Neurosci 30 2010 6355 6359
182. P. Desplats, B. Spencer, E. Coffee, P. Patel, S. Michael, and C. Patrick et al. Alpha- synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases J Biol Chem 286 2011 9031 9037
183. L. Matsumoto, H. Takuma, A. Tamaoka, H. Kurisaki, H. Date, and S. Tsuji et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease PLoS One 5 2010 e15522
184. J. Richter, S. Appenzeller, O. Ammerpohl, G. Deuschl, S. Paschen, and N. Brüggemann et al. No evidence for differential methylation of α-synuclein in leukocyte DNA of Parkinson's disease patients Mov Disord 27 2012 590 591
185. T. Jonsson, J.K. Atwal, S. Steinberg, J. Snaedal, P.V. Jonsson, and S. Bjornsson et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline Nature 488 2012 96 99
186. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 2006 228 234 (Pubitemid 43238346)
187. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen et al. Alzheimer's Disease Neuroimaging Initiative Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
188. K. Blennow, H. Zetterberg, and A. Fagan Fluid biomarkers in Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006221 a006244
189. J.A. Swets Signal detection theory and ROC analysis in psychology and diagnostics: collected papers 1996 Lawrence Erlbaum Associates Mahwah, NJ
190. F. Dieterle, F. Sistare, F. Goodsaid, M. Papaluca, J.S. Ozer, and C.P. Webb et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium Nat Biotech 28 2010 455 462
191. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
192. M.S. Pepe, Z. Feng, H. Janes, P.M. Bossuyt, and J.D. Potter Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design J Natl Cancer Inst 100 2008 1432 1438
193. C.W. Daniel, R.C. Bast Jr., C.D. Berg, E.P. Diamandis, A.K. Godwin, and P. Hartge et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens Cancer Prev Res 4 2011 365 374
194. S. Srivastava The early detection research network: 10-year outlook Clin Chem 59 2013 60 67
195. J. Zhang, P. Roebuck, and K.R. Coombes Simulating gene expression data to estimate sample size for class and biomarker discovery Int J Advances Life Sci 4 2012 44 51
196. W. Tu Basic principles of statistical inference Methods Mol Biol 404 2007 53 72
197. J.E. McDermott, J. Wang, H. Mitchell, B.J. Webb-Robertson, R. Hafen, and J. Ramey et al. Challenges in biomarker discovery: Combining expert insights with statistical analysis of complex omics data Expert Opin Med Diagn 7 2013 37 51
198. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc, Series B 57 1995 289 300
199. L. Klerk, A. Broersen, I. Fletcher, R. Vanliere, and R. Heeren Extended data analysis strategies for high resolution imaging MS: New methods to deal with extremely large image hyperspectral datasets Int J Mass Spectrom 260 2007 222 236
200. T. Alexandrov MALDI imaging mass spectrometry: statistical data analysis and current computational challenges BMC Bioinformatics 13 Suppl. 16 2012 S11 S24
201. D.C. Anderson, W. Li, D.G. Payan, and W.S. Noble A new algorithm for the evaluation of shotgun peptide sequencing in proteomics: Support vector machine classification of peptide MS/MS spectra and SEQUEST scores J Proteome Res 2 2003 137 146 (Pubitemid 37099049)
202. A. Barla, G. Jurman, S. Riccadonna, S. Merler, M. Chierici, and C. Furlanello Machine learning methods for predictive proteomics Brief Bioinform 9 2008 119 128 (Pubitemid 351516998)
203. J. Luts, F. Ojeda, R. Van de Plas, B. De Moor, S. Van Huffel, and J.A. Suykens A tutorial on support vector machine-based methods for classification problems in chemometrics Anal Chim Acta 665 2010 129 145
204. C. Kingsford, and S.L. Salzberg What are decision trees? Nat Biotechnol 26 2008 1011 1013
205. R. Diaz-Uriarte, and S. Alvarez de Andres Gene selection and classification of microarray data using random forest BMC Bioinformatics 7 2006 3
206. S.E. O'Bryant, G. Xiao, R. Barber, R. Huebinger, K. Wilhelmsen, and M. Edwards et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI PLoS One 6 2011 e28092
207. Z. Zhang, Y. Yu, F. Xu, A. Berchuck, C. van Haaften-Day, and L.J. Havrilesky et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer Gynecol Oncol 107 3 2007 526 531 (Pubitemid 350160868)
208. P.D. Wagner, and S. Srivastava New paradigms in translational science research in cancer biomarkers Transl Res 159 2012 343 353
209. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, and M. Cronin et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826 (Pubitemid 40051905)
210. M.J. Heller DNA microarray technology: devices, systems, and applications Annu Rev Biomed Eng 4 2002 129 153 (Pubitemid 35217417)
211. M.J. van de Vijver, Y.D. He, L.J. van't Veer, H. Dai, A.A. Hart, and D.W. Voskuil et al. A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009 (Pubitemid 35461656)
212. L.J. van 't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, and M. Mao et al. Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536 (Pubitemid 34130608)
213. D.C. Anderson Alzheimer's disease biomarkers: more than molecular diagnostics Drug Dev Res 74 2013 92 111
214. E. Nagele, M. Han, C. Demarshall, B. Belinka, and R. Nagele Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera PLoS One 6 2011 e23112 e23119
215. C. Carter Alzheimer's disease: APP, gamma secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and their relationships with herpes simplex, C. pneumoniae, other suspect pathogens, and the immune system Int J Alzheimers Dis 2011 501862 501896
216. T. Colasanti, C. Barbati, G. Rosano, W. Malorni, and E. Ortona Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression Autoimmun Rev 9 2010 807 811
217. S.E. O'Bryant, G. Xiao, R. Barber, J. Reisch, R. Doody, and T. Fairchild et al. A serum protein-based algorithm for the detection of Alzheimer disease Arch Neurol 67 2010 1077 1081
218. B.R. Lemoine, S. Rayburn, and R.S. Benton Data fusion and feature selection for Alzheimer's disease Lecture Notes Comp Sci 6334 2010 320 327
219. G. Di Paolo, and T.W. Kim Linking lipids to Alzheimer's disease: cholesterol and beyond Nat Rev Neurosci 12 2011 284 296
220. Food and Drug Administration Challenge and Opportunity on the Critical Path to New Medical Products 2004 US Dept. of Health and Human Services See also www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm
221. F.M. Goodsaid, F.W. Frueh, and W. Mattes Strategic paths for biomarker qualification Toxicology 245 2008 219 223
222. D. Warnock, and C. Peck A roadmap for biomarker qualification Nat Biotechnol 28 2010 444 445
223. F.D. Sistare, F. Dieterle, S. Troth, D.J. Holder, D. Gerhold, and D. Andrews-Cleavenger et al. Towards consensus practices to qualify safety biomarkers for use in early drug development Nat Biotechnol 5 2010 446 454
224. J. Bonventre, V. Vaidya, R. Schmouder, P. Feig, and F. Dieterle Next-generation biomarkers for detecting kidney toxicity Nat Biotechnol 28 2010 436 440
225. M.S. Pepe, R. Etzioni, Z. Feng, J.D. Potter, M.L. Thompson, and M. Thornquist et al. Phases of biomarker development for early detection of cancer J Natl Cancer Inst 93 2001 1054 1061 (Pubitemid 32717537)
226. Z. Feng, J. Kagan, M. Pepe, M. Thornquist, J. Ann Rinaudo, and J. Dahlgren et al. The Early Detection Research Network's specimen reference sets: paving the way for rapid evaluation of potential biomarkers Clin Chem 59 2013 68 74
227. W. Amin, H. Singh, L.A. Dzubinski, R.E. Schoen, and A.V. Parwani Design and utilization of the colorectal and pancreatic neoplasm virtual biorepository: An early detection research network initiative J Pathol Inform 1 2010 22 41
228. S.A. Tomlins, B. Laxman, S.M. Dhanasekaran, B.E. Helgeson, X. Cao, and D.S. Morris et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer Nature 448 2007 595 599 (Pubitemid 47206938)
229. C. Kumar-Sinha, S.A. Tomlins, and A.M. Chinnaiyan Recurrent gene fusions in prostate cancer Nat Rev Cancer 8 2008 497 511
230. D. Hessels, F.P. Smit, G.W. Verhaegh, J.A. Witjes, E.B. Cornel, and J.A. Schalken Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer Clin Cancer Res 13 2007 5103 5108 (Pubitemid 47502077)
231. J.B. de Kok, G.W. Verhaegh, R.W. Roelofs, D. Hessels, L.A. Kiemeney, and T.W. Aalders et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695 2698 (Pubitemid 34462754)
232. S.A. Tomlins, S.M. Aubin, J. Siddiqui, R.J. Lonigro, L. Sefton-Miller, and S. Miick et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA Sci Transl Med 3 94 2011 ra72
233. S. Hoshimoto, T. Shingai, D.L. Morton, C. Kuo, M.B. Faries, and K. Chong et al. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial J Clin Oncol 30 2012 3819 3826
234. T.J. Hiltermann, M.M. Pore, A. van den Berg, W. Timens, H.M. Boezen, and J.J. Liesker et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor Ann Oncol 23 2012 2937 2942
235. T.M. Gorges, and K. Pantel Circulating tumor cells as therapy-related biomarkers in cancer patients Cancer Immunol Immunother 62 2013 931 939
236. S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C.R. Jack, and W. Jagust et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimer's Dementia 1 2005 55 66 (Pubitemid 43348857)
237. M.W. Weiner, P.S. Aisen, C.R. Jack Jr., W.J. Jagust, J.Q. Trojanowski, and L. Shaw et al. Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's disease neuroimaging initiative: progress report and future plans Alzheimer's Dementia 6 2010 202 211 e7
238. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, and R.C. Green et al. Alzheimer's Disease Neuroimaging Initiative, The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimer's Dementia 8 1 Suppl 2012 S1 S68
239. C.R. Jack Jr., M.A. Bernstein, B.J. Borowski, J.L. Gunter, N.C. Fox, and P.M. Thompson et al. Alzheimer's Disease Neuroimaging Initiative. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative Alzheimer's Dementia 6 2010 212 220
240. C.R. Jack Jr., P. Vemuri, H. Wiste, S. Weigand, and T. Lesnick et al. Shapes of the trajectories of five major biomarkers of Alzheimer's disease Arch Neurol 69 2012 857 867
241. D. Galasko, M. Klauber, R. Hofstetter, D. Salmon, B. Lasker, and L. Thal The mini-mental state examination in the early diagnosis of Alzheimer's Disease Arch Neurol 47 1990 49 52 (Pubitemid 20024154)
242. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, and P.S. Aisen et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
243. R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, and A. Goate et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 367 2012 795 804
244. W. Thies, and L. Bleiler Alzheimer's disease facts and figures Alzheimer's Dementia 7 2011 208 244
245. B. Jedynak, A. Lang, B. Liu, E. Katz, and Y. Zhang et al. A computational ADNI datasets have been used to examine general features of this model Neuroimage 63 2012 1478 1486
246. S.D. Han, J. Gruhl, L. Beckett, H. Dodge, and N. Stricker et al. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease Brain Imaging Behav 6 2012 610 620
247. Y. Cui, B. Liu, S. Luo, X. Zhen, and M. Fan et al. Alzheimer's Disease Neuroimaging Initiative Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors PLoS One 6 2011 e21896
248. Y. Liu, J. Mattila, Ruiz M.Á., T. Paajanen, J. Koikkalainen, and M. van Gils et al. Alzheimer's Disease Neuroimaging Initiative. Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool PLoS One 8 2013 e55246
249. D. Zhang, and D. Shen Alzheimer's Disease Neuroimaging Initiative. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers PLoS One 7 2012 e33182
250. J. Price, and J. Morris Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 1999 358 368 (Pubitemid 29120041)
251. P.M. Bossuyt, J.B. Reitsma, D.E. Bruns, C. Gatsonis, and P. Glasziou et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy Clin Chem 49 2003 1 6 (Pubitemid 36078546)
252. F. Goodsaid, and F. Frueh Process map proposal for the validation of genomic biomarkers Pharmacogenomics 7 2006 773 782 (Pubitemid 44225912)
253. R. Simon Clinical trials for predictive medicine Statist Med 31 2012 3031 3040
254. S. Matsui Genomic biomarkers for personalized medicine: development and validation in clinical studies Comp Math Methods Med 2013 article ID 865980
255. S. Mandrekar, M. An, and D. Sargent A review of phase II trial designs for initial marker validation Contemp Clin Trials May 8 2013
256. S. Kern Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures Cancer Res 72 2012 6097 6101
257. J. Ioannidis Biomarker failures Clin Chem 59 2013 202 204
258. S. Srivastava Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network - a collaborative approach Gastrointestinal Cancer Res 1 Suppl. 2 2007 S60 S63
259. A. Burton Big science for a big problem: ADNI enters its second phase Lancet Neurol 10 2011 206 207
260. R.E. Becker, and N.H. Greig Alzheimer's disease drug development: old problems require new priorities CNS Neurol Disord Drug Targets 7 2008 499 511
261. B. Friedlin, L. McShane, and E. Korn Randomized clinical trials with biomarkers: design issues J Natl Cancer Inst 102 2010 152 160
262. D. Ransohoff Bias as a threat to the validity of cancer molecular-marker research Nature 5 2005 142 149 (Pubitemid 40215862)
263. I. Jacobs, and U. Menon The Sine Qua Non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples Cancer Prev Res 4 2011 299 302
264. D.W. Cramer, R.C. Bast Jr., C.D. Berg, E.P. Diamandis, and A.K. Godwin et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens Cancer Prev Res 4 2011 365 374
265. C.S. Zhu, P.F. Pinsky, D.W. Cramer, D. Ransohoff, and P. Hartage et al. A Framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer Cancer Prev Res 4 2011 375 383
266. S. Bradbury, and W. Jakoby Glycerol as an enzyme-stabilizing agent: effects on aldehyde dehydrogenase Proc Nat Acad Sci USA 69 1972 2373 2376
267. G.C. Harris Jr., and M.J. Sweeney Changes in the protein concentration of chicken seminal plasma after rapid freeze-thaw Cryobiology 7 1970 209 215
268. K. Pikal-Cleland, N. Rodriguez-Hornedo, G. Amidon, and J. Carpenter Protein denaturation during freezing and thawing in phosphate buffer systems: Monomeric and tetrameric beta-galactosidase Arch Biochem Biophys 384 2000 398 406 (Pubitemid 32012817)
269. E. Cao, Y. Chen, Z. Cui, and P. Foster Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions Biotechnol Bioeng 82 2002 684 690 (Pubitemid 36576232)
270. Affymetrix, Sample Pooling for Microarray Analysis: A Statistical Assessment of Risks and Biases. Technical Note, no. 701494 Rev. 2, 2004
271. S. Sadiq, and D. Agranoff Pooling serum samples may lead to loss of potential biomarkers in SELDI-ToF MS proteomic profiling Proteome Sci 6 2008 16 23
272. A. Telaar, G. Nurnberg, and D. Repsilber Finding biomarker signatures in pooled sample designs: a simulation framework for methodological comparisons Adv Bioinf 2010 318473
273. N.L. Anderson, and N.G. Anderson The human plasma proteome: history, character, and diagnostic prospects Mol Cell Proteomics 1 2002 845 867
274. T. Shi, J.Y. Zhou, M.A. Gritsenko, M. Hossain, D.G. Camp 2nd, and R.D. Smith et al. IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery Methods 56 2012 246 253
275. C. Tu, P.A. Rudnick, M.Y. Martinez, K.L. Cheek, S.E. Stein, and R.J. Slebos et al. Depletion of abundant plasma proteins and limitations of plasma proteomics J Proteome Res 9 2010 4982 4991
276. S. Surinova, R. Schiess, R. Huttenhain, F. Cerciello, B. Wollscheid, and R. Aebersold On the development of plasma protein biomarkers J Proteome Res 10 2010 5 16
277. C. Cray Acute phase proteins in animals Prog Mol Biol Transl Sci 105 2012 113 150
278. C. Cray, J. Zaias, and N.H. Altman Acute phase response in animals: a review Comp Med 59 2009 517 526
279. J.J. Ceron, P.D. Eckersall, and S. Martýnez-Subiela Acute phase proteins in dogs and cats: current knowledge and future perspectives Vet Clin Pathol 34 2005 85 99 (Pubitemid 40799488)
280. J.T. Leek, R.B. Scharpf, H.C. Bravo, D. Simcha, B. Langmead, and W.E. Johnson et al. Tackling the widespread and critical impact of batch effects in high-throughput data Nat Rev Genet 11 2010 733 739
281. J. Hu, K.R. Coombes, J.S. Morris, and K.A. Baggerly The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales Brief Funct Genomic Proteomic 3 2005 322 331 (Pubitemid 40468216)
282. K.A. Baggerly, K.R. Coombes, and E.S. Neeley Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer J Clin Oncol 26 2008 1187 1188 1186-7; author reply
283. P.A. Kyzas, K.T. Loizou, and J.P. Ioannidis Selective reporting biases in cancer prognostic factor studies J Natl Cancer Inst 97 2005 1043 1055 (Pubitemid 41417921)
284. A. Potti, H.K. Dressman, A. Bild, R.F. Riedel, G. Chan, and R. Sayer et al. Genomic signatures to guide the use of chemotherapeutics Nat Med 12 2006 1294 1300 (Pubitemid 44706932)
285. A. Potti, H.K. Dressman, A. Bild, R.F. Riedel, G. Chan, and R. Sayer et al. Retraction: genomic signatures to guide the use of chemotherapeutics Nat Med 17 2011 135
286. K.A. Baggerly, and K.R. Coombes Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology Annal Appl Statistics 3 2009 1309 1334
287. K.A. Baggerly, and K.R. Coombes What information should be required to support clinical "omics" publications? Clin Chem 57 2011 688 690
288. S. Michiels, S. Koscielny, and C. Hill Prediction of cancer outcome with microarrays: a multiple random validation strategy Lancet 365 2005 488 492 (Pubitemid 40215731)
289. E.T. Fossel, J.M. Carr, and J. McDonagh Detection of malignant tumors, Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma N Engl J Med 315 1986 1369 1376 (Pubitemid 17055408)
290. R. Shulman NMR-another cancer-test disappointment New Engl J Med 322 1990 1002 1003
291. P. Okunieff, A. Zietman, J. Kahn, S. Singer, L.J. Neuringer, and R.A. Levine et al. Lack of efficacy of water- suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors N Engl J Med 322 1990 953 958 (Pubitemid 20146629)
292. H. Maecker, T. Lindstrom, W. Robinson, P. Utz, and M. Hale et al. New tools for classification and monitoring of autoimmune diseases Nat Rev Rheumatol 8 2012 317 328
293. D. Hayes, and C. Paoletti Circulating tumour cells: insights into tumour heterogeneity J Intern Med 274 2013 137 143
294. S. Krishnamurthy, F. Bischoff, J. Ann Mayer, K. Wong, and T. Pham et al. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer Cancer Med 2 2013 226 233
295. M. Pestrin, S. Bessi, F. Galardi, M. Truglia, and A. Biggeri et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients Breast Cancer Res Treat 118 2009 523 530